Operator: Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full-Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of.
- Accepted abstracts include preclinical data on JAG101, an investigational gene therapy designed to address the root cause of Type 1 galactosemiaLAKE FOREST, Ill. (BUSINESS WIRE) Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic dise.